Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus

References

• Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214–20.
   PubMed Web of Science ®Google Scholar
• Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265–73.
   PubMed Web of Science ®Google Scholar
• The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.
   Google Scholar
• Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol 2002;28:173–89.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Diamond B. Lupus and the central nervous system. Lupus 2008;17:376–9.
   PubMed Web of Science ®Google Scholar
• Brundin L, Svenungsson E, Morcos E, Andersson M, Olsson T, Lundberg I, . Central nervous system nitric oxide formation in cerebral systemic lupus erythematosus. Ann Neurol 1998;44:704–6.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, . Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001;60:372–9.
   PubMed Web of Science ®Google Scholar
• Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1992;1:111–17.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644–9.
   PubMed Web of Science ®Google Scholar
• Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992;35:417–22.
   PubMed Web of Science ®Google Scholar
• DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189–93.
   PubMed Web of Science ®Google Scholar
• Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, . Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006;103:19854–9.
   PubMed Web of Science ®Google Scholar
• Lai NS, Lan JL. Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations. Lupus 2000;9:353–7.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Gustafsson J, Leonard D, Sandling J, Gunnarsson I, Nordmark G, . A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2009;69:834–40.
   PubMed Web of Science ®Google Scholar
• Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397–401.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231–64.
   PubMed Web of Science ®Google Scholar
• Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263–75.
   PubMed Web of Science ®Google Scholar
• Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235–46.
   PubMed Web of Science ®Google Scholar
• Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, . Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375–83.
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, . Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065–7.
   PubMed Web of Science ®Google Scholar
• Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313–19.
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. J Clin Immunol 2005;25:189–201.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Masterman T, Rot U, Duvefelt K, Brynedal B, Karrenbauer VD, . Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005;167:210–14.
   PubMed Web of Science ®Google Scholar
• Please provide further details for this reference.www.hgsi.com/belimumab.html, accessed 2 March 2011.
   Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, . T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004;172:7169–76.
   PubMed Web of Science ®Google Scholar
• Mattsson M, Moller B, Lundberg I, Gard G, Bostrom C. Reliability and validity of the Fatigue Severity Scale in Swedish for patients with systemic lupus erythematosus. Scand J Rheumatol 2008;37:269–77.
   PubMed Web of Science ®Google Scholar
• Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351–6.
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–3.
   PubMed Web of Science ®Google Scholar
• Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, . Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48:1566–71.
   PubMed Web of Science ®Google Scholar
• Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler 2005;11:198–202.
   PubMed Web of Science ®Google Scholar
• George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, . BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195–200.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Masterman T, Hillert J, Moerk S, Jonsson R. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 2007;65:92–8.
   PubMed Web of Science ®Google Scholar
• Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003;48:2881–7.
   PubMed Web of Science ®Google Scholar
• Lima I, Melo A, Brandi IV, Costa O, Santiago M. Lupoid sclerosis: what is the role of antiphospholipid antibodies? J Clin Rheumatol 2007;13:85–6.
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, . Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096–103.
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, . Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167.
   PubMed Web of Science ®Google Scholar
• Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, . BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005;52:2080–91.
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, . Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697–710.
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, . BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34–9.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, . Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007;34:2056–62.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, . Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007;46:1083–6.
   PubMed Web of Science ®Google Scholar
• Moses N, Wiggers J, Nicholas C, Cockburn J. Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005;57:30–8.
   PubMed Web of Science ®Google Scholar
• Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol 1998;25:892–5.
   PubMed Web of Science ®Google Scholar
• Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002;29:482–6.
   PubMed Web of Science ®Google Scholar
• Ronnback L, Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflamm 2004;1:22.
   PubMed Web of Science ®Google Scholar
• Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142–50.
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, . Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724–34.
   PubMed Web of Science ®Google Scholar